• Xia Zhao, Hui-Fang Ding, Juan Liu, Guo-Qiang Liu, Min Xu, Jian Xing, and Cai-Feng Sun.
• Department of Hematology, The Central Hospital of Shengli Oil Field, Dongying 257000, Shandong Province, China.
• Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Dec 1; 23 (6): 1633-7.

ObjectiveTo evaluate the treatment value of adoptive immunotherapy (dendritic cells and cytokine-induced killer cells, DC-CIK) combined with chemotherapy on patients with multiple myeloma (MM) and its effect on secreting function of T lymphocytes in MM patients.MethodsA total of 36 patients with MM were randomly divided into two groups, among them 28 patients in chemotherapy group were treated by chemotherapy only, 28 patients in combined therapy group were treated by adoptive immunotherapy (DC-CIK) combined with chemotherapy, and the clinical outcomes and the levels of IL-2, IFN-γ, IL-4, IL-10 secreted by T lymphocytes between two groups were compared.ResultsAfter treatment, the quality of life, clinical index and survival in combined therapy group were better than those in chemotherapy group (P <0.05); the levels of IL-2 and IFN-γ in combined therapy group was higher than these in chemotherapy group (P <0.05), and the levels of IL-4 and IL-10 in combined therapy group were lower than those in chemotherapy group (P <0.05).ConclusionDC-CIK combined with chemotherapy can be an effective and promising treatment for patients with MM, and it maybe strengthen the anti-tumor action of bodies by regulating the balance between Th1 and Th2 reaction.

11 keywords...

hide…